Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.

"The complete response rate, consistent treatment response and safety profile across multiple clinical studies to date with HyBryte™ has been exciting to see," noted Dr. Kim, Principal Investigator of ...

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).

The efficacy and safety of a proposed biosimilar and ustekinumab are similar among adults with moderate to severe plaque psoriasis.

Psoriasis is more than just a skin condition – it’s an autoimmune disorder that can manifest as scales, spots, or even ...

The association between psoriasis severity and CVD may be mediated by systemic inflammation, with a statistically significant indirect effect observed.

Vietnam Psoriasis Therapeutics Market Key Takeaways: ...

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

The VISIBLE trial revolutionizes psoriasis research with strategies boosting diversity and rapid enrollment, addressing gaps ...